Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma

Author(s):
IJzendoorn, D.G.P. van; Sleijfer, S.; Gelderblom, H.; Eskens, F.A.L.M.; Leenders, G.J.L.H. van; Szuhai, K. (0000-0002-1228-4245); Bovee, J.V.M.G. (0000-0003-1155-0481)
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-06-01
Language
English
Is part of
Clinical Cancer Research (2018), Vol. 24, no. 11, p. 2678-2687
hdl
1887/87142
doi
10.1158/1078-0432.CCR-17-3512